Newly Recognized Genetic Tumor Syndromes of the CNS in the 5th WHO Classification: Imaging Overview with Genetic Updates

References

1. 1.↵
   WHO Classification of Tumours Editorial Board. Central Nervous System Tumors. 5th ed. International Agency for Research on Cancer; 2022 (beta online version)
2. 2.↵
   WHO Classification of Tumours Editorial Board. Genetic Tumour Syndromes. 5th ed. International Agency for Research on Cancer; 2021
3. 3.↵
   2. Carta R,
   3. Del Baldo G,
   4. Miele E, et al

   . Cancer predisposition syndromes and medulloblastoma in the molecular era. Front Oncol 2020;10:566822 doi:10.3389/fonc.2020.566822 pmid:33194646

   CrossRefPubMed
4. 4.↵
   2. Noortman WA,
   3. Vriens D,
   4. Geus LF, et al

   . FDG-PET/CT radiomics for the identification of genetic clusters in pheochromocytomas and paragangliomas. Eur Radiol 2022;32:7227–36 doi:10.1007/s00330-022-09034-5 pmid:36001126

   CrossRefPubMed
5. 5.↵
   2. Karabacak M,
   3. Ozkara BB,
   4. Ozturk A, et al

   . Radiomics-based machine learning models for prediction of medulloblastoma subgroups: a systematic review and meta-analysis of the diagnostic test performance. Acta Radiol 2023;64:1994–200 doi:10.1177/02841851221143496 pmid:36510435

   CrossRefPubMed
6. 6.↵
   2. Sohn B,
   3. An C,
   4. Kim D, et al

   . Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant. J Neurooncol 2021;155:267–76 doi:10.1007/s11060-021-03870-z pmid:34648115

   CrossRefPubMed
7. 7.↵
   2. Rimkus TK,
   3. Carpenter RL,
   4. Qasem S, et al

   . Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers (Basel) 2016;8:22 doi:10.3390/cancers8020022 pmid:26891329

   CrossRefPubMed
8. 8.↵
   2. Waszak SM,
   3. Robinson GW,
   4. Gudenas BL, et al

   . Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature 2020;580:396–401 doi:10.1038/s41586-020-2164-5 pmid:32296180

   CrossRefPubMed
9. 9.↵
   2. Fruehwald-Pallamar J,
   3. Puchner SB,
   4. Rossi A, et al

   . Magnetic resonance imaging spectrum of medulloblastoma. Neuroradiology 2011;53:387–96 doi:10.1007/s00234-010-0829-8 pmid:21279509

   CrossRefPubMed
10. 10.↵
    2. Tauziède-Espariat A,
    3. Guerrini-Rousseau L,
    4. Perrier A, et al

    . Immunohistochemistry as a tool to identify ELP1-associated medulloblastoma. Acta Neuropathol 2022;143:523–25 doi:10.1007/s00401-022-02409-4 pmid:35199222

    CrossRefPubMed
11. 11.↵
    2. Walpole S,
    3. Pritchard AL,
    4. Cebulla CM, et al

    . Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. J Natl Cancer Inst 2018;110:1328–41 doi:10.1093/jnci/djy171 pmid:30517737

    CrossRefPubMed
12. 12.↵
    2. Shankar GM,
    3. Abedalthagafi M,
    4. Vaubel RA, et al

    . Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol 2017;19:535–45 doi:10.1093/neuonc/now235 pmid:28170043

    CrossRefPubMed
13. 13.↵
    2. Kerr K,
    3. Qualmann K,
    4. Esquenazi Y, et al

    . Familial syndromes involving meningiomas provide mechanistic insight into sporadic disease. Neurosurgery 2018;83:1107–18 doi:10.1093/neuros/nyy121 pmid:29660026

    CrossRefPubMed
14. 14.↵
    2. Shankar GM,
    3. Santagata S

    . BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol 2017;19:1447–56 doi:10.1093/neuonc/nox094 pmid:28482042

    CrossRefPubMed
15. 15.↵
    2. Rai K,
    3. Pilarski R,
    4. Cebulla CM, et al

    . Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet 2016;89:285–94 doi:10.1111/cge.12630 pmid:26096145

    CrossRefPubMed
16. 16.↵
    2. LaFave LM,
    3. Béguelin W,
    4. Koche R, et al

    . Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med 2015;21:1344–49 doi:10.1038/nm.3947 pmid:26437366

    CrossRefPubMed
17. 17.↵
    2. Caroleo AM,
    3. De Ioris MA,
    4. Boccuto L, et al

    . DICER1 syndrome and cancer predisposition: from a rare pediatric tumor to lifetime risk. Front Oncol 2020;10:614541 doi:10.3389/fonc.2020.614541 pmid:33552988

    CrossRefPubMed
18. 18.↵
    2. Schultz KA,
    3. Yang J,
    4. Doros L, et al

    . DICER1-pleuropulmonary blastoma familial tumor predisposition syndrome: a unique constellation of neoplastic conditions. Pathol Case Rev 2014;19:90–100 doi:10.1097/PCR.0000000000000027 pmid:25356068

    CrossRefPubMed
19. 19.↵
    2. de Kock L,
    3. Priest JR,
    4. Foulkes WD, et al

    . An update on the central nervous system manifestations of DICER1 syndrome. Acta Neuropathol 2020;139:689–701 doi:10.1007/s00401-019-01997-y pmid:30953130

    CrossRefPubMed
20. 20.↵
    2. de Kock L,
    3. Sabbaghian N,
    4. Plourde F, et al

    . Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathol 2014;128:111–22 doi:10.1007/s00401-014-1285-z pmid:24839956

    CrossRefPubMed
21. 21.↵
    2. Schultz KA,
    3. Williams GM,
    4. Kamihara J, et al

    . DICER1 and associated conditions: identification of at-risk individuals and recommended surveillance strategies. Clin Cancer Res 2018;24:2251–61 doi:10.1158/1078-0432.CCR-17-3089 pmid:29343557

    Abstract/FREE Full Text
22. 22.↵
    2. Bertherat J,
    3. Horvath A,
    4. Groussin L, et al

    . Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab 2009;94:2085–91doi:10.1210/jc.2008-2333 pmid:19293268

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Espiard S,
    3. Vantyghem MC,
    4. Assié G, et al

    . Frequency and incidence of Carney complex manifestations: a prospective multicenter study with a three-year follow-up. J Clin Endocrinol Metab 2020;105:dgaa002 doi:10.1210/clinem/dgaa002 pmid:31912137

    CrossRefPubMed
24. 24.↵
    2. Bovée JV

    . Osteochondromyxoma. In: WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. Classification of Tumours Series. Vol. 3. 5th ed. International Agency for Research on Cancer; 2020
25. 25.↵
    2. Stratakis CA,
    3. Kirschner LS,
    4. Carney JA

    . Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001;86:4041–46 doi:10.1210/jcem.86.9.7903 pmid:11549623

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Yeom JA,
    3. Song YS,
    4. Lee IS, et al

    . Malignant melanotic nerve sheath tumors in the spinal canal of psammomatous and non-psammomatous type. World J Clin Cases 2022;10:8735–41 doi:10.12998/wjcc.v10.i24.8735 pmid:36157803

    CrossRefPubMed
27. 27.↵
    2. Chan AK,
    3. Han SJ,
    4. Choy W, et al

    . Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. Clin Neuropathol 2017;36:213–21 doi:10.5414/NP301022 pmid:28699883

    CrossRefPubMed
28. 28.↵
    2. Kaufman DK,
    3. Kimmel DW,
    4. Parisi JE, et al

    . A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma. Neurology 1993;43:1728–31 doi:10.1212/wnl.43.9.1728 pmid:8414022

    CrossRefPubMed
29. 29.↵
    2. Sargen MR,
    3. Merrill SL,
    4. Chu EY, et al

    . CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature. Br J Dermatol 2016;175:785–89 doi:10.1111/bjd.14485 pmid:26876133

    CrossRefPubMed
30. 30.↵
    2. Baker MJ,
    3. Goldstein AM,
    4. Gordon PL, et al

    . An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies. J Med Genet 2016;53:721–27 doi:10.1136/jmedgenet-2015-103446 pmid:26794401

    Abstract/FREE Full Text
31. 31.↵
    2. Boedeker CC,
    3. Hensen EF,
    4. Neumann HP, et al

    . Genetics of hereditary head and neck paragangliomas. Head Neck 2014;36:907–16 doi:10.1002/hed.23436 pmid:23913591

    CrossRefPubMed
32. 32.↵
    2. Turchini J,
    3. Cheung VK,
    4. Tischler AS, et al

    . Pathology and genetics of phaeochromocytoma and paraganglioma. Histopathology 2018;72:97–105 doi:10.1111/his.13402 pmid:29239044

    CrossRefPubMed
33. 33.↵
    2. Fishbein L,
    3. Leshchiner I,
    4. Walter V, et al

    ; Cancer Genome Atlas Research Network. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 2017;31:181–93 doi:10.1016/j.ccell.2017.01.001 pmid:28162975

    CrossRefPubMed
34. 34.↵
    2. Lin EP,
    3. Chin BB,
    4. Fishbein L, et al

    . Head and neck paragangliomas: an update on the molecular classification, state-of-the-art imaging, and management recommendations. Radiol Imaging Cancer 2022;4:e210088 doi:10.1148/rycan.210088 pmid:35549357

    CrossRefPubMed
35. 35.↵
    2. Ota Y,
    3. Liao E,
    4. Capizzano AA, et al

    . Diagnostic role of diffusion-weighted and dynamic contrast-enhanced perfusion MR imaging in paragangliomas and schwannomas in the head and neck. AJNR Am J Neuroradiol 2021;42:1839–46 doi:10.3174/ajnr.A7266 pmid:34446460

    Abstract/FREE Full Text
36. 36.↵
    2. Janssen I,
    3. Blanchet EM,
    4. Adams K, et al

    . Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 2015;21:3888–95 doi:10.1158/1078-0432.CCR-14-2751 pmid:25873086

    Abstract/FREE Full Text
37. 37.↵
    2. Nalepa G,
    3. Clapp DW

    . Fanconi anaemia and cancer: an intricate relationship. Nat Rev Cancer 2018;18:168–85 doi:10.1038/nrc.2017.116 pmid:29376519

    CrossRefPubMed
38. 38.↵
    2. Ameziane N,
    3. May P,
    4. Haitjema A, et al

    . A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51. Nat Commun 2015;6:8829 doi:10.1038/ncomms9829 pmid:26681308

    CrossRefPubMed
39. 39.↵
    2. Kutler DI,
    3. Patel KR,
    4. Auerbach AD, et al

    . Natural history and management of Fanconi anemia patients with head and neck cancer: a 10-year follow-up. Laryngoscope 2016;126:870–79 doi:10.1002/lary.25726 pmid:26484938

    CrossRefPubMed
40. 40.↵
    2. Miele E,
    3. Mastronuzzi A,
    4. Po A, et al

    . Characterization of medulloblastoma in Fanconi anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup. Biomark Res 2015;3:13 doi:10.1186/s40364-015-0038-z pmid:26064523

    CrossRefPubMed
41. 41.↵
    2. Niedermayer I,
    3. Reiche W,
    4. Graf N, et al

    . Cerebroretinal vasculopathy and leukoencephalopathy mimicking a brain tumor: report of two early-onset cases with Fanconi’s anemia-like phenotypes suggesting an autosomal-recessive inheritance pattern. Clin Neuropathol 2000;19:285–95 pmid:11128621

    PubMed
42. 42.↵
    2. Dewire MD,
    3. Ellison DW,
    4. Patay Z, et al

    . Fanconi anemia and biallelic BRCA2 mutation diagnosed in a young child with an embryonal CNS tumor. Pediatr Blood Cancer 2009;53:1140–42 doi:10.1002/pbc.22139 pmid:19530235

    CrossRefPubMed
43. 43.↵
    2. Rushlow DE,
    3. Mol BM,
    4. Kennett JY, et al

    . Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol 2013;14:327–34 doi:10.1016/S1470-2045(13)70045-7 pmid:23498719

    CrossRefPubMedWeb of Science
44. 44.↵
    2. de Jong MC,
    3. Kors WA,
    4. de Graaf P, et al

    . Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol 2014;15:1157–67 doi:10.1016/S1470-2045(14)70336-5 pmid:25126964

    CrossRefPubMed
45. 45.↵
    2. Kivelä T

    . Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 1999;17:1829–37 doi:10.1200/JCO.1999.17.6.1829 pmid:10561222

    Abstract/FREE Full Text
46. 46.↵
    2. Miller CW,
    3. Aslo A,
    4. Won A, et al

    . Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol 1996;122:559–65 doi:10.1007/BF01213553 pmid:8781571

    CrossRefPubMedWeb of Science
47. 47.↵
    2. Fabius AW,
    3. Hoefen M,
    4. van Leeuwen FE, et al

    . Subsequent malignant neoplasms in retinoblastoma survivors. Cancers (Basel) 2021;13:1200 doi:10.3390/cancers13061200 pmid:33801943

    CrossRefPubMed